The acquisition of two FDA-approved migraine products from Upsher-Smith Laboratories directly benefits Tonix Pharmaceuticals by expanding its product portfolio and strengthening its position in the migraine market. This could lead to increased revenues and growth for the company, positively impacting its stock price in the short term.